Measuring X-ray anisotropy in solar flares. Prospective stereoscopic capabilities of STIX and MiSolFA

During the next solar maximum, two upcoming space-borne X-ray missions, STIX on board Solar Orbiter and MiSolFA, will perform stereoscopic X-ray observations of solar flares at two different locations: STIX at 0.28 AU (at perihelion) and up to inclinations of $\sim25^{\circ}$, and MiSolFA in a low-Earth orbit. The combined observations from these cross-calibrated detectors will allow us to infer the electron anisotropy of individual flares confidently for the first time. We simulated both instrumental and physical effects for STIX and MiSolFA including thermal shielding, background and X-ray Compton backscattering (albedo effect) in the solar photosphere. We predict the expected number of observable flares available for stereoscopic measurements during the next solar maximum. We also discuss the range of useful spacecraft observation angles for the challenging case of close-to-isotropic flare anisotropy. The simulated results show that STIX and MiSolFA will be capable of detecting low levels of flare anisotropy, for M1-class or stronger flares, even with a relatively small spacecraft angular separation of 20-30{\deg}. Both instruments will directly measure the flare X-ray anisotropy of about 40 M- and X-class solar flares during the next solar maximum. Near-future stereoscopic observations with Solar Orbiter/STIX and MiSolFA will help distinguishing between competing flare-acceleration mechanisms, and provide essential constraints regarding collisional and non-collisional transport processes occurring in the flaring atmosphere for individual solar flares

Dry turning of alumina/aluminum composites with CVD diamond coated Co-cemented tungsten carbide tools

Triangular (TPGN 160308) WC-6 wt.%Co inserts having different average grain sizes (1 and 3 µm) were submitted to surface roughening either by wet etching with Murakami's reagent or by a heat treatment in the hot filament chemical vapour deposition (HFCVD) reactor. The heat treatment was performed in a monohydrogen-rich atmosphere at substrate temperatures as high as 1000 degrees C. Scanning electron microscopy and energy-dispersive spectroscopy showed that this pre-treatment led to surface roughening of the as-ground inserts and to a lower surface Co concentration. Prior to deposition, all inserts were etched with an acid solution of hydrogen peroxide. Diamond coatings were deposited by HFCVD. The coated inserts were tested by dry machining of aluminum-matrix composite (Al-10%Al2O3) bars. Turning test results indicated that a proper combination of substrate pretreatment and microstructure can significantly improve tool life

Treatment of squamous cell carcinoma of the anal canal: A new strategies with anti-EGFR therapy and immunotherapy

The incidence of squamous cell carcinoma of the anal canal (SCAC) is increasing in both sexes but the standard treatment remains that of 20 years ago. However, interesting data have recently emerged on the use of anti-epidermal growth factor receptor (EGFR) agents and immunotherapy in advanced disease. Thus, new avenues of research are opening up that will hopefully lead to more effective therapeutic strategies. We provide an overview of the latest studies published on this tumor and discuss the possible future therapeutic options for combination therapy, anti-EGFR treatment and radiotherapy

The prognostic role of hemoglobin levels in patients undergoing concurrent chemo-radiation for anal cancer

Background: Concurrent chemo-radiation (CT-RT) is a standard therapy for squamous cell carcinoma of anal canal. Different clinical and biological factors may potentially affect outcome. We investigated the prognostic role of baseline hemoglobin (Hb) in a cohort of anal cancer patients submitted to CT-RT with 5-fluorouracil and mitomycin C. Methods: Up to 161 patients with clinical stage T1-T4/N0-N3/M0 were treated. Response was assessed at 6 weeks and thereafter at 3, 6 and 12 months. Two different approaches were used:a)simultaneous integrated boost following RTOG 05-29 indications;b)first sequence of 45Gy/25 fractions to the pelvis followed by 9-14.4 Gy/5-8 fractions to the macroscopic disease. Primary endpoints were progression-free survival (PFS) and overall survival (OS). Results: On multivariate analysis, pre-treatment Hb level had a significant correlation to OS (HR:0.53;95% CI:0.33-0.87; p = 0.001), but not to PFS (HR:0.78;95% CI:0.53-1.15; p = 0.12) Patients with pre-treatment Hb ≥ 12 g/dl had 5-year PFS and OS of 82.2%, compared to 29.3% and 32.8% for those below the threshold. The likelihood to achieve a complete remission increased by 5.6% for every single-unit (g/dl) increase in baseline Hb level over 11 g/dl. On multivariate analysis, response to treatment had a significant correlation to PFS (incomplete vs complete response - HR:5.43;95% CI:2.75-10.7; p < 0.0001) and OS (HR: 6.96;95% CI:2.96-16.5; p < 0.0001). Conclusions: We showed that baseline Hb level is a strong indicator for poor response to RT-CT in anal cancer patients. A close clinical monitoring for incomplete response to treatment should be advised in patients with low pre-treatment Hb. The hypothesis that the preservation of adequate Hb level during treatment may lead to a better outcome needs prospective evaluation

The AMS-02 Time of Flight System. Final Design

The AMS-02 detector is a superconducting magnetic spectrometer that will operate on the International Space Station. The time of flight (TOF) system of AMS-02 is composed by four scintillator planes with 8, 8, 10, 8 counters each, read at both ends by a total of 144 phototubes. This paper describes the new design, the expected performances, and shows preliminary results of the ion beam test carried on at CERN on October 2002.Comment: 4 pages, 6 EPS figures. Proc. of the 28th ICRC (2003

The European Network for Translational Research in Atrial Fibrillation (EUTRAF): objectives and initial results.

Atrial fibrillation (AF) is the most common sustained arrhythmia in the general population. As an age-related arrhythmia AF is becoming a huge socio-economic burden for European healthcare systems. Despite significant progress in our understanding of the pathophysiology of AF, therapeutic strategies for AF have not changed substantially and the major challenges in the management of AF are still unmet. This lack of progress may be related to the multifactorial pathogenesis of atrial remodelling and AF that hampers the identification of causative pathophysiological alterations in individual patients. Also, again new mechanisms have been identified and the relative contribution of these mechanisms still has to be established. In November 2010, the European Union launched the large collaborative project EUTRAF (European Network of Translational Research in Atrial Fibrillation) to address these challenges. The main aims of EUTRAF are to study the main mechanisms of initiation and perpetuation of AF, to identify the molecular alterations underlying atrial remodelling, to develop markers allowing to monitor this processes, and suggest strategies to treat AF based on insights in newly defined disease mechanisms. This article reports on the objectives, the structure, and initial results of this network

Immune-related adverse events in the treatment of non-Hodgkin lymphoma with immune checkpoint inhibitors

Immune checkpoint inhibitors (ICIs) show efficacy in the treatment of non-Hodgkin lymphomas (NHL). However, these agents are associated with a unique group of side effects called immune-related adverse events (irAEs). We conducted an observational retrospective/prospective study on patients with relapsed/refractory NHL treated with ICI to determine the incidence of irAEs assessing the type, severity, and timing of onset, outcome and relationship with study drugs of these events. Thirty-two patients underwent ICI as single agent (N = 20) or in combination (N = 12). Ten patients (31.3%) developed at least one irAE for a total of 17 irAEs. Median time to presentation of irAEs was 69&nbsp;days (range 0–407) with a median resolution time of 16&nbsp;days (range 0–98). Progression free survival at 24&nbsp;months for patients who developed an irAE was 40% and 31.8% for who did not. Overall survival for the two groups did not differ (at 24&nbsp;months 40.0% and 62.5% for patients without and with irAE, respectively), but the median for who developed an irAE was not reached. The incidence of irAEs was associated with better long-term survival in NHL treated with ICIs but patients’ disease conditions need to be carefully evaluated to decide the optimal management